Objective: The purpose of this study was to clarify the long-term clinical outcome of elderly patients with localized aggressive lymphoma and to explore appropriate treatment strategies for this population. Methods: Subjects of this multicenter prospective study were untreated patients aged !70 years with aggressive Stage IA -IIA lymphoma. Therapy with 80%-dose CHOP (cyclophosphamide 600 mg/m 2 , doxorubicin 40 mg/m 2 , vincristine 1.1 mg/m 2 and prednisolone 80 mg/ day for 5 days) was repeated every 3 weeks. After three cycles of chemotherapy, involvedfield radiotherapy was performed with 30-50 Gy in 15-28 fractions. Results: A total of 24 patients (median age, 75 years; range, 70 -84 years) were enrolled. Nineteen patients (79%) had non-bulky tumors ,6 cm. The median follow-up period was 7.3 years. The 7-year overall and progression-free survival rates were 78.9% (95% confidence interval, 62.3 -95.5) and 65.3% (95% confidence interval, 45.3 -85.3), respectively. Six patients developed systemic relapse, two of them after 6 years. The median survival time after relapse was only 5 months (range, 2 weeks -5.2 years). Five patients developed second malignancies, and three other patients died from other causes without lymphoma progression. None of the patients developed local relapse within the radiation field and/or regional relapse in adjacent lymph node areas. Conclusions: Although systemic relapses, short survival time after relapse and death from other causes occurred, no loco-regional relapses were observed. Less intensive radiotherapy such as low-dose and small field might not compromise the treatment outcome for this population.
INTRODUCTION
Non-Hodgkin's lymphoma (NHL) is a disease with high incidence in the elderly. The incidence rate of aggressive NHL increases with age (1). Nearly one-half of all newly diagnosed cases occur in patients older than 60 years (2) , and the outcome of elderly patients is poor due to aggressive disease subtype and diminished organ function (2, 3) . Many clinical trials have demonstrated the benefits of systemic chemotherapy in patients with aggressive NHL, and standard treatment schedules, which can be applied to the majority of elderly patients, have been investigated (2, 4) . Some investigators have reported unacceptable toxicity due to aggressive therapy in elderly patients, and Balducci and Lyman (5) emphasized that patients older than 70 years are at high risk for neutropenic infection (6) . In general, elderly patients have been considered too frail to receive the standard treatment and have instead received low-intensity treatment schedules. The US National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program demonstrated that even in 1999, nearly 50% of elderly patients were still not receiving doxorubicin-based chemotherapy, which has gained general acceptance for use among the elderly (7) . Older age, congestive heart failure and other co-morbidities are associated with treatment without doxorubicin.
On the other hand, the Groupe d'Etude des Lymphomes de l'Adulte (GELA) conducted a prospective randomized trial to evaluate the administration of full-dose CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone), with or without rituximab (Rituxan; Roche), in elderly patients (60 -80 years old), and showed that these two fulldose regimens were safe for elderly patients aged 80 years (8) . In general, patients participating in prospective clinical trials do not have severe co-morbidities and have good performance status, and thus full-dose chemotherapy is safe for such elderly patients. The gap between prospective clinical trials and clinical practice should be reduced to improve the level of clinical practice for elderly patients with NHL. To this end, we previously conducted a multicenter prospective study to evaluate the efficacy and safety of 80%-dose threecourse CHOP followed by involved-field radiotherapy for elderly patients with localized aggressive NHL and reported that this regimen was safe for patients aged over 70 years (9) .
The purpose of the present study was to clarify the clinical status of elderly patients after long-term follow-up and explore appropriate treatment strategies for elderly patients with localized aggressive NHL.
PATIENTS AND METHODS

PATIENTS
Elderly patients aged !70 years with localized aggressive NHL were recruited between December 2000 and February 2004. Eligibility criteria were reported in detail previously (9) . Histological subtypes were diffuse large B-cell, peripheral T-cell or anaplastic large cell lymphoma according to the World Health Organization classification, and localized diseases included Stage IA or IIA (10) . All patients had good performance status (0 -2) according to the Eastern Cooperative Oncology Group (ECOG) classification. Patients were excluded from the trial if they had a history of active cancer during the previous 5 years, co-morbidity with other serious medical conditions including severe ischemic heart disease or cardiomyopathy, positive serology for human immunodeficiency virus, or the presence of hepatitis B virus antigen or anti-hepatitis C virus antibody. All patients were required to have sufficient hematological, renal and hepatic function. Minimal staging procedures included clinical examination; chest radiography; gallium scintigraphy; computed tomography (CT) of the neck, chest, abdomen and pelvis; bone marrow biopsy; and blood studies. The staging procedure did not require positron emission tomography (PET).
This study complied fully with all provisions of the Declaration of Helsinki. All participating hospitals obtained the permission of their institutional review boards and all patients gave their written informed consent prior to entry into the study.
TREATMENT
The detailed treatment schedule and stopping rules were reported previously (9) . Reduced-dose chemotherapy (80%-dose CHOP) included cyclophosphamide 600 mg/m 2 (day 1), doxorubicin 40 mg/m 2 (day 1), vincristine 1.1 mg/ m 2 (day 1) and oral prednisolone 80 mg/day (days 1 -5). Chemotherapy was repeated at 21-day intervals. If a patient developed Grade 4 neutropenia or febrile neutropenia, all subsequent cycles were administered with granulocyte colony-stimulating factor support.
Involved-field radiotherapy was performed after three cycles of chemotherapy. The involved field was defined as the regional area including the primary lesion and involved nodes determined by pre-chemotherapy evaluations, as well as adjacent uninvolved nodes. Examples include the full Waldeyer's ring and prophylactic bilateral whole-neck fields for Stage I tonsil lymphoma, and the ipsilateral neck field between the mastoid process below the tumor and the infraclavicular lymph node for Stage I lymphoma. The radiation dose was 30 -30.6 Gy given in fractions of 15 -20 Gy over 3 -4 weeks in patients who achieved a complete response (CR) and 40 -50 Gy in 20 -28 fractions over 4 -6 weeks for those who did not achieve CR. Response was assessed using Cheson's criteria, which did not include PET examination (11) . Clinical examination was performed every 6 months for the first 5 years, and then at the discretion of the attending physician. Neck, chest and abdominal CT scans were performed after 6 months, and every 6 months thereafter during the first 5 years. After 5 years, clinical examination was performed annually and continued for as long as possible.
OUTCOME MEASURES
Endpoints included overall survival (OS), progression-free survival (PFS) and relapse pattern. Survival was measured from the date of study registration. The last follow-up date of OS was the date of death, and that of PFS was the date of death or the date of disease progression (whichever came first). Data from patients who were alive at the last follow-up were censored. OS rate was calculated using death from any cause as an event, and PFS rate was calculated using disease progression or death from any cause as an event. Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria grading system, version 2.0. OS and PFS rates were calculated using the Kaplan -Meier method. All patients were included in analyses of efficacy and safety. The log-rank test was used to compare survival distributions of different groups using a significance level of 0.05. Statistical analyses were performed with JMP software version 5.1 (SAS Institute, Cary, NC, USA). Tumor responses were classified as CR, CR unconfirmed (CRu), partial response (PR), stable disease or progressive disease according to the proposed International Workshop criteria (11) .
RESULTS
TREATMENT COMPLIANCE AND TOXICITY
A total of 24 patients from eight Japanese institutions were enrolled in the study between December 2000 and February 2004. Patient characteristics are shown in Table 1 . The most popular primary sites were Waldeyer's ring and other head and neck extranodal regions. The median age was 75 years (range, 70 -84); four patients (16%) were .80 years. Three patients did not complete the study protocol; these patients received only two cycles of chemotherapy. The physician stopped the protocol in one patient, and another patient refused administration of the third round of chemotherapy. Another patient developed pancreatic cancer during chemotherapy, and the protocol was stopped. The compliance rate of the protocol was 87.5%. The administration of chemotherapy was delayed due to hematological toxicity in six patients, and the dose of chemotherapy was reduced due to hematological toxicity in one 84-year-old patient.
Severe non-hematological toxicity (Grades 3 -4) during chemotherapy occurred in four patients (infection in three patients and diabetes mellitus in one patient). Non-hematological severe toxicity (Grade 3) during radiotherapy occurred in one patient (mucositis). None of the patients died from treatment-related toxicity.
Of the 22 patients who received radiotherapy at the head and neck area, we observed mild dry mouth in 10 patients at the last follow-up. None of the patients ate soft food due to the dry mouth and thus were administered a feeding tube.
TREATMENT RESPONSE AND SURVIVAL RATES Nineteen patients (79%) had a non-bulky tumor ,6 cm in size. The response rate after chemotherapy and that after combined treatment were 79% (19 patients) and 88% (21 patients) for CR or CRu, respectively. 766 Prospective study of elderly lymphoma patients
RELAPSE AND LATE ADVERSE EVENTS
Six patients developed systemic relapse at distant sites: lung, heart, mediastinal lymph nodes, liver, adrenal gland, kidney, abdominal lymph nodes or bone marrow. Among these six patients, four had undergone the planned treatment schedule and had achieved CR or CRu after initial treatment, and two had undergone incomplete treatment and had achieved PR or stable disease. The median relapse interval from the start of initial treatment was 3 years (range, 5 months -8 years), and two patients developed systemic relapses after 6 -8 years. After systemic relapses, these patients were treated with systemic chemotherapy and/or supportive care. The median survival time after relapse was only 5 months (range, 2 weeks -5.2 years). None of the patients developed local relapse within the radiation field and/or regional relapse in the adjacent lymph node areas during the follow-up period. Five patients developed second malignancies: colon cancer in two patients, and gastric cancer, bladder cancer and pancreatic cancer in one patient each. The former four patients underwent curative surgery or endoscopic intervention. In the fifth patient, pancreatic cancer developed during initial lymphoma treatment, and he died 3 months after the present study registration. Three patients died due to other causes-cardiac failure, deterioration of general condition and sepsis without lymphoma progression-at 7 months, 4.8 and 9.3 years after registration.
DISCUSSION
More than half of all new cancer cases occur in patients aged !60 years. Despite the high frequency of cancer in this population, elderly patients have been underrepresented in clinical trials evaluating the standard of care for cancer, and few guidelines specifically address the evaluation and treatment of this population. Clinical trials have tended to exclude patients with co-morbid medical conditions, and physicians and patients prefer less toxic treatments in clinical practice. Among patients in the older age group, there is a large degree of heterogeneity in the ability to tolerate aggressive therapy, such as full-dose chemotherapy and/or definitive radiotherapy. Despite evidence that chronological age does not meaningfully influence the efficacy or toxicity of cancer treatment, elderly patients tend to receive less comprehensive cancer therapy compared with younger patients (12) . This may be due to concerns of increased toxicity, coexistence of co-morbid medical conditions, and physician or patient preference. Predicting severe toxicity due to aggressive therapy plays a large part in treatment strategy decisions for elderly individuals. The treatment strategy for elderly patients should take into account the balance between harm and benefit. The Vulnerable Elders-13 Survey (VES-13) and comprehensive geriatric assessment (CGA) are useful tools for a geriatrician's baseline evaluation of an elderly individual (13) . These programs are helpful for predicting toxicity due to treatment, estimating survival, identifying new problems during follow-up and improving general well-being (14 -16) . A weak point of our study was that we did not evaluate our study participants with VES-13 or CGA. In the future, these programs and other useful tools should be included in clinical trials to set the standard care for elderly patients with NHL.
The Southwest Oncology Group (SWOG) reported the effectiveness of three-course CHOP followed by involvedfield radiotherapy in comparison with eight-course CHOP in patients with localized NHL (17) . Three-cycle CHOP followed by involved-field radiotherapy was considered the standard care for patients with localized aggressive disease (18, 19) . Full-course chemotherapy is another standard type of care for patients with NHL. It was reported that elderly patients with NHL who had good performance status and minimal co-morbid illness could tolerate full-course chemotherapy without increased toxicity (20 -22) . However, in clinical practice, elderly patients have been considered too frail to receive the standard treatment and have been treated with low-intensity schedules (7) . We performed a prospective study to evaluate the tolerability and effectiveness of short-course 80%-dose CHOP followed by radiotherapy and reported satisfactory tolerability and survival rates in the elderly (9) . The addition of rituximab, a chimeric human/ murine immunoglobulin G1 monoclonal antibody that binds specifically to the B-cell surface antigen CD20, to the fullcourse CHOP regimen was shown to improve treatment outcome in elderly patients with advanced disease with no accompanying increase in toxicity (8, 23) . The MabThera International Trial (MInT) Group demonstrated that the addition of rituximab improved treatment outcome in patients aged ,60 years with low risk (24) . However, the clinical benefit of rituximab addition has not been clarified in patients with localized disease (25) . SWOG conducted a Phase II study (SWOG0014) that evaluated four doses of rituximab plus three-course CHOP followed by radiotherapy in patients with localized aggressive NHL and reported 4-year PFS and OS of 88 and 92%, respectively (25) . The SWOG8736 study applied short-course CHOP without rituximab in the same population and reported 4-year PFS and OS of 78 and 88%, respectively (17) . These two different Phase II studies could not be compared using statistical analysis, and thus further studies are required. Given that the median survival time following relapse in the current study was only 5 months, initial effective treatment should be applied. Rituximab and other target therapies should be evaluated to develop a more effective and less toxic therapeutic strategy for elderly patients with aggressive localized NHL.
The SWOG studies applied relatively high radiation doses of 40 Gy or more. However, no prospective randomized trials have evaluated adequate radiation doses following chemotherapy in patients with NHL (26, 27) . Wilder et al. (26) conducted a retrospective analysis and reported that the local control rate in patients with tumors larger than 3.5 cm who received a radiation dose of 39.1 Gy was only 40%. However, this analysis included only a very small number of patients, which is problematic with regard to statistical analysis. Kamath et al. (27) reported that a radiation dose of ,40 Gy led to a poor local control rate in patients with large tumors. However, in this study, the local control rate of good responders who achieved CR after chemotherapy was excellent even if they received low-dose radiotherapy (i.e. ,30 -40 Gy). Isobe et al. (28) reported a sufficient control rate in patients who received an intermediate radiation dose of 30 -40 Gy following brief chemotherapy. Yu et al. (29) analyzed 86 patients with head and neck localized aggressive NHL who received short-course chemotherapy followed by irradiation of the involved node areas and reported that whole-neck irradiation including prophylactic irradiation of the contralateral neck area was not necessary. Our study included 19 patients (79%) with non-bulky tumor ,6 cm and 16 patients (67%) with clinical Stage I lymphoma, and the response rate after chemotherapy was 79% (19 patients) for CR or CRu. Our study showed that none of the patients developed local relapse within the radiation field and/or regional relapse in the adjacent lymph node areas. Less intensive radiotherapy, such as low-dose radiation and the use of a small radiation field, should be investigated for the elderly population.
Our study indicated that late systemic relapses, short survival time after relapse, second malignancies and death from other causes occurred, and these adverse events were associated with failure to thrive, physical frailty and cognitive impairment. However, no loco-regional relapse was observed. Less intensive radiotherapy might not compromise treatment outcome for elderly patients with non-bulky and chemotherapy-responsive lymphoma.
